Protara therapeutics, inc. (PRTO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net Loss

-10,060

-1,610

-1,536

-5,315

-6,531

-5,259

-4,510

-4,879

-6,081

-5,551

-12,307

-5,608

-6,498

-6,962

-7,107

-7,905

-6,552

-6,342

-5,383

-5,072

-4,580

7,233

-5,181

-2,563

-2,831

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

28

24

-

16

9

8

9

8

6

7

Amortization of premium/discount on available-for-sale securities

-

0

0

0

4

16

21

17

-3

0

3

3

-4

-23

-37

-35

-36

-71

-165

-217

-198

-12

-12

-2

-4

Accretion of discount and debt issuance cost of convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

741

Unrealized loss on forward foreign currency contracts included in net income

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2

-53

178

-111

-314

-112

0

-

-

-

-

Foreign currency remeasurement (loss)

-

-

-

-

-

0

0

-111

136

369

83

-338

59

-82

27

-49

28

-46

-23

-6

0

-

-

-

-

Stock based compensation

2,797

-34

96

101

780

782

904

922

821

768

747

867

845

844

687

946

866

670

611

476

407

225

185

32

17

Amortization of operating lease right-of-use asset

19

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

49

0

83

22

174

32

22

29

32

33

38

37

40

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

12

69

Prepaid expenses and other current assets

76

474

-332

-401

-349

448

-193

-275

-121

752

-786

15

-278

-266

480

-129

-331

718

-238

522

-103

-1,273

754

1,221

259

Accounts payable

1,933

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-1,810

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use asset

-

0

-68

-67

-65

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest receivable

-

-7

-5

-20

15

-52

7

0

-4

-

-

-

-

72

-72

0

26

-182

16

-107

305

-13

12

16

-15

Accounts payable and accrued expenses

-

-1,032

-442

-1,178

155

544

303

-6,789

-220

146

4,957

1,114

-2,056

204

139

1,097

-367

770

122

70

296

-320

-342

1,028

589

Operating lease liability

-

0

-68

-67

-65

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-7,145

-3,140

-1,464

-5,950

-5,092

-4,313

-3,116

-10,348

-5,456

-5,698

-5,926

-3,282

-7,446

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

29

86

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,568

-5,894

-

-3,910

-4,597

-3,873

-2,050

-3,706

-2,672

-1,562

Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.

3,718

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale investments

-

-

-

-

-

-

-

-

-

-

-

-

-

0

13,038

2,997

23,721

22,508

7,246

751

58,139

-

-

-

-

Proceeds from maturities of available-for-sale investments

-

0

0

0

2,500

8,000

8,000

8,475

7,515

7,958

4,000

0

4,920

15,340

12,189

18,800

13,614

31,753

28,432

12,359

2,961

-

-

-

-

Proceeds from sale of available-for-sale investments

-

-

-

-

-

0

0

0

1,999

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of available-for-sale investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,355

Purchase of property and equipment

247

0

0

0

16

95

3

12

9

12

9

8

6

12

57

194

8

27

135

31

5

-

-

-

-

Net cash provided by/(used in) investing activities

3,471

0

0

0

2,484

5,413

6,003

-2,494

9,505

6,447

-14,092

-13,368

4,914

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,609

-10,115

-

23,057

11,577

-55,183

3,679

-1,686

-16,831

2,355

Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

1

0

1,182

105

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of stock options

-

-

-

-

-

-

-

-

-

-1

0

1

108

41

17

127

12

39

42

7

0

-

-

-

-

Proceeds from - ArTara Private Placement, net of offering costs

1,867

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from - Proteon Private Placement, net of offering costs

12,413

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from - Series 1 Convertible Preferred Stock, net of offering costs

25,318

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments under short-term debt

370

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

39,228

-

-

-

-

-

-

-

-

59

21,536

1,241

213

-

-

-

-

-

-

-

-

-

-

-

-

Net increase/(decrease) in cash and cash equivalents and restricted cash

35,554

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-2

0

-113

137

376

83

-338

59

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in cash, cash equivalents and restricted cash

-

-3,140

-1,464

-5,950

-2,608

1,146

5,740

-12,871

4,186

1,184

1,601

-15,747

-2,260

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

132

12

-

42

59

0

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

-49

28

-46

-23

-6

0

-

-

-

-

Decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,508

10,124

-15,969

4,048

19,166

7,033

-59,056

65,601

-5,407

5,060

793

Supplemental cash flow information
Cash paid for:
Interest

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses

121

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of insurance agreement with notes payable

1,668

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.

34,532

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

667

2,277

1,897

1,512

Fair value of derivative embedded within convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,512